Vanda Pharmaceuticals

May 23, 2012

2009: Biotech’s Stealth Small Cap Rally

January 3, 2010 By MD Becker Partners 2 Comments

On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009. Nonetheless, at the start of the year we [...]

Filed Under: Articles Tagged With: Amgen, AMGN, AMLN, Amylin Pharmaceuticals, BIIB, Biogen Idec, biotechnology, BTK, CELG, Celgene, Dendreon, DNDN, ENZN, Enzon Pharmaceuticals, GENZ, Genzyme General, GILD, Gilead Sciences, GTx Inc, GTXI, HGSI, Human Genome Sciences, Impax Laboratories, IPXL, life sciences, NASDAQ Biotech Index, NBI, NPS Pharmaceuticals, NPSP, NYSE Arca Biotechnology Index, OGXI, Oncogenex Pharmaceuticals, OSIR, Osiris Therapeutics, PGNX, Progenics Pharmaceuticals, Salix Pharmaceuticals, Santarus, SLXP, SNGX, SNTS, Soligenix, Vanda Pharmaceuticals, VNDA

Five key principles for life science companies to not only survive – but thrive – in the current environment

June 3, 2009 By MD Becker Partners Leave a Comment

On May 7, 2009, MD Becker Partners LLC hosted its inaugural life sciences roundtable titled “Successful Strategies for Raising Visibility and Capital.” The meeting brought together experts from leading investment banks, life sciences companies, venture investment groups, and the media to discuss the issues surrounding effective two-way communication between a company, the financial community, the [...]